拉斯维加斯9888

----------------

SEMINAR 1

----------------

Title（标题）：客户决策治理的技术创新 - 量化决策治理

Time（功夫）：2011年3月24日（周四）下午2:00－3:00

Place（地址）：拉斯维加斯9888新楼217教室

Speaker（汇报人）：Mr. Yachen Lin 广发银行首席风险官

Abstract（提要）：

客户的行为阐发能够暗示成一个多维数据向量，巨大数量的客户行为组成了一个多维向量的海量数据

；诳突形⒓凑夂Ａ渴荨⒃趺茨芰κ姑骋拙霾咦龅蕉灾⑾乱⒕伎凸邸⒆钪占蠡霾呋乇？答案是量化决策治理
。

量化决策治理是目前世界上最先进的决策治理步骤
。那么，什么是量化决策治理？它的主题技术是什么？它的发展趋向和市场价值怎么？它在中国大陆利用又若何呢？这些问题都将在这次的汇报中得到回覆
。

----------------

SEMINAR 2

----------------

Title（标题）：Development of analytic methods for genome-scale RNAi screens

Time（功夫）：2011年3月24日（周四）下午3:30－4:30

Speaker（汇报人）：Xiaohua Douglas Zhang, Ph.D.

Associate Director, Department of Biometrics Research

Merck Research Laboratories

Abstract（提要）：

RNA interference (RNAi) is a mechanism in living cells that helps determine what genes are active and how active they are. The development of algorithms for RNAi design that produce potent and selective knockdown of targeted genes has led to a great deal of interest in using RNAi to elucidate gene function, to identify novel targets for drug discovery, and to reveal the molecular biological system. The importance of RNAi was further recognized when the Nobel Prize in Medicine and Physiology was awarded to Drs. Fire and Mello in 2006 for their research in this field. The genome-scale RNAi study allows genome-wide loss-of-function screening. One of the major advantages of the genome-scale RNAi researches is their ability to simultaneously interrogate thousands of genes. With the ability of generating a large amount of data per experiment, the genome-scale RNAi researches have led to an explosion in the rate of data generated in recent years. Consequently, one of the most fundamental challenges in the genome-scale RNAi researches is to glean biological significance from mounds of data, which relies on the development and adoption of statistics/bioinformatics methods that are suitable for analyzing RNAi screens. Recently, we have been developing novel analytic methods specifically for quality control and hit selection in genome-scale RNAi screens. I will present these recently developed analytic methods and demonstrate how to use them in RNAi high-throughput screens.

About the speaker（汇报人介绍）：

Dr. Xiaohua Douglas Zhang is an Associate Director, Scientific Staff, in Merck Research Laboratories. He got his Ph.D. in statistics from Carnegie-Mellon University, PA, USA, an MS in Genetics and a BS in Biology from Beijing Normal University, China. He has worked on analyzing data generated from new biotechnologies. He has analyzed many high-throughput screening (HTS) projects for many years. Merck has put great effort into RNAi research. It purchased Sirna for $1.1 billion in 2006 and has one of the largest labs for conducting RNAi/compound HTS. Since early 2005, Dr. Zhang has led data analysis in RNAi HTS projects at Merck and has continuously developed and adopted experimental designs and analytic methods for HTS projects including novel analytic methods for quality controls and hit selection, which allows him and his colleagues to continuously publish papers in t